Profusa to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Profusa (NASDAQ: PFSA), a commercial stage digital health company focused on continuous biochemistry monitoring technology, has announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference. CEO Ben Hwang, Ph.D., will deliver a corporate overview at the event, which takes place September 8-10, 2025 at the Lotte New York Palace Hotel.
The presentation will be available on demand to registered conference attendees starting September 5, 2025, at 7:00 AM ET. Investors can register for the conference and request one-on-one meetings through the conference website.
Profusa (NASDAQ: PFSA), azienda digitale nel settore sanitario focalizzata su tecnologie per il monitoraggio biochimico continuo, ha annunciato la propria partecipazione al H.C. Wainwright 27th Annual Global Investment Conference. Il CEO Ben Hwang, Ph.D., presenterà una panoramica aziendale durante l'evento, che si terrà dal 8 al 10 settembre 2025 presso il Lotte New York Palace Hotel.
La presentazione sarà disponibile on demand per i partecipanti registrati a partire dal 5 settembre 2025 alle 7:00 AM ET. Gli investitori possono registrarsi alla conferenza e richiedere incontri one-to-one attraverso il sito web dell'evento.
Profusa (NASDAQ: PFSA), compañía digital de salud en fase comercial centrada en tecnología de monitorización bioquímica continua, ha anunciado su participación en la H.C. Wainwright 27th Annual Global Investment Conference. El CEO Ben Hwang, Ph.D., ofrecerá una presentación corporativa en el evento, que se celebrará del 8 al 10 de septiembre de 2025 en el Lotte New York Palace Hotel.
La presentación estará disponible bajo demanda para los asistentes registrados a partir del 5 de septiembre de 2025 a las 7:00 AM ET. Los inversores pueden registrarse en la conferencia y solicitar reuniones individuales a través del sitio web del evento.
Profusa (NASDAQ: PFSA)는 연속 생화학 모니터링 기술에 주력하는 상업 단계의 디지털 헬스 기업으로, H.C. Wainwright 27th Annual Global Investment Conference에 참가한다고 발표했습니다. CEO Ben Hwang 박사가 행사에서 회사 개요를 발표할 예정이며, 행사는 2025년 9월 8일~10일에 롯데 뉴욕 팰리스 호텔에서 열립니다.
발표 영상은 2025년 9월 5일 오전 7:00 ET부터 등록된 참가자에게 온디맨드로 제공됩니다. 투자자들은 컨퍼런스 웹사이트를 통해 등록하고 일대일 미팅을 요청할 수 있습니다.
Profusa (NASDAQ: PFSA), société de santé numérique en phase commerciale spécialisée dans la technologie de surveillance biochimique continue, a annoncé sa participation à la H.C. Wainwright 27th Annual Global Investment Conference. Le PDG Ben Hwang, Ph.D., présentera un aperçu de l'entreprise lors de l'événement, qui se tiendra du 8 au 10 septembre 2025 à l'hôtel Lotte New York Palace.
La présentation sera disponible à la demande pour les participants inscrits à partir du 5 septembre 2025 à 7h00 ET. Les investisseurs peuvent s'inscrire à la conférence et demander des rendez-vous individuels via le site web de la conférence.
Profusa (NASDAQ: PFSA), ein kommerzielles Digital-Health-Unternehmen mit Fokus auf kontinuierliche biochemische Überwachungstechnologie, hat seine Teilnahme an der H.C. Wainwright 27th Annual Global Investment Conference angekündigt. CEO Ben Hwang, Ph.D., wird bei der Veranstaltung einen Unternehmensüberblick präsentieren. Die Konferenz findet vom 8. bis 10. September 2025 im Lotte New York Palace Hotel statt.
Die Präsentation steht registrierten Konferenzteilnehmern ab dem 5. September 2025 um 7:00 AM ET on demand zur Verfügung. Investoren können sich über die Konferenzwebsite anmelden und Einzelgespräche anfragen.
- None.
- None.
Berkeley, Calif, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (NASDAQ: PFSA), a commercial stage digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an individual’s biochemistry, announces that Ben Hwang, Ph.D., Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 27th Annual Global Investment Conference. The conference is being held on September 8 – 10, 2025 at the Lotte New York Palace Hotel.
Dr. Hwang’s presentation will be available on demand beginning Friday, September 5 at 7:00am ET for registered investors of the conference. To request a one-on-one meeting and to register for the conference, click below:
https://hcwevents.com/annualconference/
About Profusa
Based in Berkeley, Calif., Profusa is a commercial stage digital health company led by visionary scientific founders, an experienced management team and a world-class board of directors in the development of a new generation of tissue-integrated sensors to detect and continuously transmit actionable, medical-grade data for personal and medical use. With its long-lasting, injectable and affordable biosensors and its intelligent data platform, Profusa aims to provide people with a personalized biochemical signature rooted in data that clinicians can trust and rely on.
“LUMEE”, “PROFUSA” and the PROFUSA logo are registered trademarks of Profusa Inc. in the United States, Canada, European Union, China, Japan, South Korea and Australia. For more information, visit https://profusa.com.
Special Note Regarding Forward-Looking Statements
Certain statements in this press release may be considered “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or future financial or operating performance of Profusa. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “future,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “propose,” “seek,” “should,” “strive,” “will,” or “would” or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which may be beyond the control of Profusa and could cause actual results to differ materially from those expressed or implied by such forward-looking statements, including risks regarding the highly volatile nature of the price of Bitcoin and other cryptocurrencies, as well as the risk that the Company's stock price may be highly correlated to the price of the digital assets that it holds. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Profusa and its management, are inherently uncertain. Profusa cautions you that these statements are based on a combination of facts and factors currently known and projections of the future, which are inherently uncertain. There are risks and uncertainties described in our Form S-1 Registration Statement (Registration No. 333-289461) filed with the SEC on August 11, 2025, and described in other documents filed by Profusa from time to time with the SEC. These filings may identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Profusa cannot assure you that the forward-looking statements in this communication will prove to be accurate.
Contacts
Investor and Media Contacts email: info@coreir.com
Phone: 1 (212) 655-0924
